Buloxibutid (C21) – PAH

Preclinical data in pulmonary hypertension models shows that buloxibutid reverses vascular remodeling and significantly improves hemodynamics.

Strong preclinical data in disease-relevant animal model. Vicore data on file.

In combination with the effects on small resistance vessels, demonstrated in both healthy volunteers and diseased tissue in Systemic Sclerosis patients where buloxibutid promotes vascular function and increases local blood flow, the data supports clinical development in PAH (Pulmonary Arterial Hypertension).